Artificial and bioartificial support systems for liver failure.

BACKGROUND Artificial and bioartificial liver support systems may 'bridge' patients with acute or acute-on-chronic liver failure to liver transplantation or recovery. OBJECTIVES To evaluate beneficial and harmful effects of artificial and bioartificial support systems for acute and acute-on-chronic liver failure. SEARCH STRATEGY Trials were identified through The Cochrane Hepato-Biliary Group Controlled Trials Register (September 2002), The Cochrane Central Register of Controlled Trials on The Cochrane Library (Issue 3, 2002), MEDLINE (1966 - September 2002), EMBASE (1985 - September 2002), and The Chinese Biomedical Database (September 2002), manual searches of bibliographies and journals, authors of trials, and pharmaceutical companies. SELECTION CRITERIA Randomised clinical trials on artificial or bioartificial support systems for acute or acute on-chronic liver failure were included irrespective of blinding, publication status, or language. Non-randomised studies were included in explorative analyses. DATA COLLECTION AND ANALYSIS Data were extracted independently by three reviewers. Results were presented as relative risks (RR) with 95% confidence intervals (CI). Sources of heterogeneity were explored through sensitivity analyses and meta-regression. The primary outcome was mortality. MAIN RESULTS Twelve trials on artificial or bioartificial support systems versus standard medical therapy (483 patients) and two trials comparing different artificial support systems (105 patients) were included. Most trials had unclear methodological quality. Compared to standard medical therapy, support systems had no significant effect on mortality (RR 0.86; 95% CI 0.65-1.12) or bridging to liver transplantation (RR 0.87; 95% CI 0.73-1.05), but a significant beneficial effect on hepatic encephalopathy (RR 0.67; 95% CI 0.52-0.86). Meta-regression indicated that the effect of support systems depended on the type of liver failure (P = 0.03). In subgroup analyses, artificial support systems appeared to reduce mortality by 33% in acute-on-chronic liver failure (RR 0.67; 95% CI 0.51-0.90), but not in acute liver failure (RR 0.95; 95% CI 0.71-1.29). Two trials comparing artificial support systems showed significant mortality reductions with intermittent versus continuous haemofiltration (RR 0.58; 95% CI 0.36-0.94) and no significant difference between five versus ten hours of charcoal haemoperfusion (RR 1.03; 95% CI 0.65-1.62). The incidence of adverse events was inconsistently reported. REVIEWER'S CONCLUSIONS This Review indicates that artificial support systems may reduce mortality in acute-on-chronic liver failure. Artificial and bioartificial support systems did not appear to affect mortality in acute liver failure. However, considering the strength of the evidence additional randomised clinical trials are needed before any support system can be recommended for routine use.

[1]  E. Frazzoli,et al.  Early Experiences with a Porcine Hepatocyte-based Bioartificial Liver in Acute Hepatic Failure Patients , 2002 .

[2]  A. Demetriou,et al.  Bioartificial liver support. , 2001, Journal of hepato-biliary-pancreatic surgery.

[3]  S. Mitzner,et al.  Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[4]  S. Cohen,et al.  Treatment of acetaminophen-induced fulminant hepatic failure with a bioartificial liver. , 1997, Transplantation proceedings.

[5]  V. Sørensen,et al.  Improvement of systemic vascular resistance and arterial pressure in patients with acute on chronic liver failure during treatment with the molecular adsorbent recycling system (mars) , 2001 .

[6]  P. Sorkine,et al.  Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure , 2001, Critical care medicine.

[7]  P. J. Brock,et al.  Extracorporeal pig-liver perfusoon in treatment of hepatic coma due to fulminant hepatitis. , 1971, Lancet.

[8]  P. Russell.  Understanding resource use in liver transplantation. , 1999, JAMA.

[9]  M. Moritz,et al.  Perioperative management of fulminant and subfulminant hepatic failure with therapeutic plasmapheresis. , 1989, Transplantation proceedings.

[10]  R. Hughes,et al.  Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure. , 1998, Artificial organs.

[11]  J. Stange,et al.  TREATMENT OF ACUTE AND CHRONIC HEPATIC FAILURE WITH THE MARS SYSTEM - CLINICAL RESULTS , 1996 .

[12]  N. Sussman,et al.  The Hepatix extracorporeal liver assist device: initial clinical experience. , 1994, Artificial organs.

[13]  J. Bion,et al.  Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation , 2005, Intensive Care Medicine.

[14]  M. Strauss,et al.  Primary or established liver cells for a hybrid liver? Comparison of metabolic features. , 1995, ASAIO journal.

[15]  R. Hughes,et al.  Temporary Extracorporeal Liver Support for Severe Acute Alcoholic Hepatitis Using the Biologic-Dt , 1998, The International journal of artificial organs.

[16]  R. Williams,et al.  Classification, Etiology, and Considerations of Outcome in Acute Liver Failure , 1996, Seminars in liver disease.

[17]  Plevris,et al.  The management of acute liver failure , 1998 .

[18]  S. Thung,et al.  ORTHOTOPIC LIVER TRANSPLANTATION FOR WILSON’S DISEASE: A SINGLE-CENTER EXPERIENCE , 2001, Transplantation.

[19]  K. Imai,et al.  Rationality of plasma exchange therapy based on periodic liver CT volume calculation in patients with fulminant hepatitis. , 1990, Progress in clinical and biological research.

[20]  A. Davenport,et al.  Changes in intracranial pressure during haemofiltration in oliguric patients with grade IV hepatic encephalopathy. , 1989, Nephron.

[21]  A. Demetriou,et al.  Clinical Experience with a Porcine Hepatocyte-Based Liver Support System , 1996, The International journal of artificial organs.

[22]  S. Ash,et al.  Push-pull sorbent-based pheresis and hemodiabsorption in the treatment of hepatic failure: preliminary results of a clinical trial with the BioLogic-DTPF System. , 2000, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[23]  A. Demetriou,et al.  Clinical Use of a Bioartificial Liver in the Treatment of Acetaminophen-Induced Fulminant Hepatic Failure , 1999, The American surgeon.

[24]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[25]  J. Burnell,et al.  Acute hepatic coma treated by cross-circulation or exchange transfusion. , 1967, The New England journal of medicine.

[26]  R. Williams,et al.  Experiences in the treatment of fulminant hepatic failure by conservative therapy, charcoal haemoperfusion, and polyacrylonitrile haemodialysis. , 1978, The International journal of artificial organs.

[27]  Rahman,et al.  Review article: liver support systems in acute hepatic failure , 1999, Alimentary pharmacology & therapeutics.

[28]  J. Furui,et al.  Effects of recombinant human hepatocyte growth factor on the proliferation and function of porcine hepatocytes. , 2000, ASAIO journal.

[29]  E. Will,et al.  Hemodynamics and survival of patients with acute renal failure treated by continuous dialysis with two synthetic membranes. , 1998, Artificial organs.

[30]  Y. Fujita,et al.  Clinical trial of plasmapheresis in hepatic failure. , 1982, Transactions - American Society for Artificial Internal Organs.

[31]  P. Laterre,et al.  An interim analysis of a phase II/III prospective randomized, multicenter, controlled trial of the HepatAssist (R) bioartificial liver support system for the treatment of fulminant hepatic failure. , 2001 .

[32]  Jianpin Liu,et al.  Artificial and bioartificial support systems for liver failure: a Cochrane Hepato-Biliary Group Protocol. , 2002, Liver.

[33]  P. Opolon,et al.  Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane. , 1978, Gut.

[34]  A. Nissenson,et al.  Hemodiabsorption in treatment of hepatic failure. , 1998, Journal of transplant coordination : official publication of the North American Transplant Coordinators Organization.

[35]  A. Hartz,et al.  A comparison of observational studies and randomized, controlled trials , 2000, American journal of ophthalmology.

[36]  S. Ash.  Hemodiabsorption in treatment of acute hepatic failure and chronic cirrhosis with ascites. , 1994, Artificial organs.

[37]  R. Hughes,et al.  Use of Bioartificial and Artificial Liver Support Devices , 1996, Seminars in liver disease.

[38]  A. Demetriou,et al.  Treatment of Severe Liver Failure with a Bioartificial Liver a , 1997, Annals of the New York Academy of Sciences.

[39]  R Williams,et al.  Extracorporeal support and hepatocyte transplantation in acute liver failure and cirrhosis , 1999, Journal of gastroenterology and hepatology.

[40]  Christian Gluud,et al.  Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. , 2003, JAMA.

[41]  A D Oxman,et al.  The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials , 1998, BMJ.

[42]  A. Davenport,et al.  Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. , 1993, Kidney international. Supplement.

[43]  G. Alexander,et al.  Combined transplantation of the heart, lung, and liver , 2001, The Lancet.

[44]  D. Palmes,et al.  Liver bridging techniques in the treatment of acute liver failure. , 2000, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[45]  R. I. Hansen,et al.  Pig liver perfusion in the treatment of acute hepatic failure. , 1971, Scandinavian journal of gastroenterology. Supplement.

[46]  J. Gerlach,et al.  Treatment of acute liver failure: hybrid liver support , 1999, Langenbeck's Archives of Surgery.

[47]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[48]  N. Andrikopoulos,et al.  The Production of Platelet-Activating Factor (PAF) during Hemodialysis with Cuprophane Membrane. Does the Calcium Concentration in the Dialysate Play Any Role on It? , 1995, The International journal of artificial organs.

[49]  S. Bhatia,et al.  Advances in bioartificial liver devices , 2001, Hepatology.

[50]  N. Tygstrup.  Perspectives in therapeutic pig liver perfusions. , 1972, Scandinavian journal of gastroenterology.

[51]  A. Davenport,et al.  Continuous vs. intermittent forms of haemofiltration and/or dialysis in the management of acute renal failure in patients with defective cerebral autoregulation at risk of cerebral oedema. , 1991, Contributions to nephrology.

[52]  Deng Jianting.  Clinical study on the treatment of fatal hepatitis with artificial liver support system , 2000 .

[53]  T. Risler,et al.  Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[54]  Christian Gluud,et al.  Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses , 2001, Annals of Internal Medicine.

[55]  L. Kramer,et al.  A Controlled Study of Sorbent Suspension Dialysis in Chronic Liver Disease and Hepatic Encephalopathy , 2001, The International journal of artificial organs.

[56]  J. O'grady,et al.  Fulminant hepatitis in patients with chronic liver disease , 2000, Journal of viral hepatitis.

[57]  J. Neuberger,et al.  Assessing priorities for allocation of donor liver grafts: survey of public and clinicians , 1998, BMJ.

[58]  E. H. Dunlop,et al.  Charcoal haemoperfusion in the treatment of fulminant hepatic failure. , 1974, Lancet.

[59]  S J Pocock,et al.  Randomized trials or observational tribulations? , 2000, The New England journal of medicine.

[60]  S R Ash,et al.  Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). , 1992, The International journal of artificial organs.

[61]  A. Gimson,et al.  Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. , 1988, Gastroenterology.

[62]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[63]  Y. Liaw,et al.  Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure , 1999, Journal of gastroenterology and hepatology.

[64]  J. Ijzermans,et al.  Extracorporeal perfusion for the treatment of acute liver failure. , 2000, Annals of surgery.

[65]  H O Jauregui,et al.  The technology of biological extracorporeal liver assist devices: from infancy to adolescence. , 2008, Artificial organs.

[66]  S. Mitzner,et al.  Albumin dialysis using the molecular adsorbent recirculating system , 2001, Current opinion in nephrology and hypertension.

[67]  S. Mitzner,et al.  Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. , 2001, Journal of the American Society of Nephrology : JASN.

[68]  A. Redeker,et al.  Controlled trial of exchange-transfusion therapy in fulminant hepatitis. , 1973, Lancet.

[69]  S. Hollis,et al.  What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999, BMJ.

[70]  Roger Williams,et al.  Classification of acute liver failure , 1993, The Lancet.

[71]  Kazuaki Inoue,et al.  Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure. , 2008, Artificial organs.

[72]  Achilles A. Demetriou,et al.  Development of a Hybrid Bioartificial Liver , 1993, Annals of surgery.

[73]  Molecular Adsorbents Recirculating System (MARS) for acute decompensation of chronic liver disease: an early clinical experience , 2003 .

[74]  J. Gerlach,et al.  Development of a Hybrid Liver Support System: A Review , 1996, The International journal of artificial organs.

[75]  A. Demetriou,et al.  Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. , 1997, Annals of surgery.

[76]  R Williams,et al.  Pilot‐controlled trial of the extracorporeal liver assist device in acute liver failure , 1996, Hepatology.

[77]  N. Tygstrup,et al.  Cerebral Blood Flow Velocity during High Volume Plasmapheresis in Fulminant Hepatic Failure , 1994, The International journal of artificial organs.

[78]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[79]  W. Meyers,et al.  Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. , 1994, The New England journal of medicine.

[80]  R. Hughes,et al.  Effect of ELAD Liver Support on Plasma HGF and TGF–β1 in Acute Liver Failure , 1996, The International journal of artificial organs.

[81]  J. Benhamou,et al.  [6 cases of severe hepatitis treated by interhuman crossed circulation]. , 1971, Annales de medecine interne.

[82]  D. Cook,et al.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.

[83]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[84]  R. Hughes,et al.  Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure , 1994, The International journal of artificial organs.

[85]  N. Sussman,et al.  Extracorporeal liver support: cell-based therapy for the failing liver. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[86]  C. Mullon,et al.  Overview of Extracorporeal Liver Support Systems and Clinical Results , 1999, Annals of the New York Academy of Sciences.

[87]  L. Kramer,et al.  Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[88]  A. Gimson,et al.  EARLIER CHARCOAL HAEMOPERFUSION IN FULMINANT HEPATIC FAILURE , 1982, The Lancet.

[89]  M. Löhr,et al.  Liver support by extracorporeal blood purification: A clinical observation , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[90]  M. Löhr,et al.  Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. , 1999, Artificial organs.

[91]  I. Bersohn,et al.  The influence of diet on serumtriglycerides in South Africa white and Bantu prisoners. , 1961, Lancet.

[92]  M. Lepore,et al.  Plasmapheresis with Plasma Exchange in Hepatic Coma. , 1969 .

[93]  T. Matsuura,et al.  Developments in bioartificial liver research: concepts, performance, and applications , 2000, Journal of Gastroenterology.

[94]  S. Pocock.  Statistical and ethical issues in monitoring clinical trials. , 1993, Statistics in medicine.

[95]  Alistair Lee,et al.  What progress with artificial livers? , 2001, The Lancet.

[96]  Massimo Malago,et al.  Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study , 2002, Hepatology.

[97]  T C Chalmers,et al.  Randomized versus historical controls for clinical trials. , 1982, The American journal of medicine.

[98]  M. Rikimaru,et al.  Hybrid bioartificial liver in hepatic failure: preliminary clinical report. , 1987, Surgery.

[99]  D. Milliner,et al.  Postdilution hemofiltration in the management of acute hepatic failure: a pilot study. , 1988, Mayo Clinic proceedings.

[100]  E. Laterre,et al.  DEANOL IN SPONTANEOUS AND INDUCED DYSKINESIAS , 1975, The Lancet.

[101]  M. Lepore,et al.  Plasmapheresis with plasma exchange in hepatic coma. Methods and results in five patients with acute fulminant hepatic necrosis. , 1970, Annals of internal medicine.

[102]  B. Eiseman,et al.  Heterologous liver perfusion in treatment of hepatic failure. , 1965, Annals of surgery.

[103]  R Peto,et al.  Trials: the next 50 years , 1998, BMJ.

[104]  L. Vīksna,et al.  Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency. , 1989, Resuscitation.

[105]  K BOCZKOWSKI,et al.  CHROMOSOMAL ENDOREDUPLICATION IN A CASE OF TURNER'S SYNDROME WITH 44/XX KARYOTYPE. , 1965, Lancet.